Mallinckrodt Plc Issues FY14 Guidance - Quick Facts

(RTTNews) - Mallinckrodt plc (MNK), a global specialty pharmaceuticals business, reported financial guidance for its fiscal year ending September 26, 2014. The company expects its fiscal 2014 annual net sales to be in the range of $2.15 billion to $2.25 billion on an operational basis, which excludes the impact of fluctuations in foreign currency exchange rates. For fiscal 2014, Mallinckrodt expects adjusted earnings per share to be in the range of $2.45 to $2.65.

Mallinckrodt expects net sales for the Specialty Pharmaceuticals segment to be in the range of $1.22 billion to $1.27 billion. The company noted that this forecast includes net sales of at least $120 million for generic version of Concerta extended-release tablets USP. Net sales for the Global Medical Imaging segment are expected to be in the range of $885 million to $930 million.

Analysts polled by Thomson Reuters expect the company to report profit per share of $2.41 on revenue of $2.17 billion for fiscal 2014. Analysts' estimates typically exclude special items.